ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K on March 16, 2023, under Items 2.02 and 9.01. The filing announces the release of financial results for the fourth quarter and full year ended December 31, 2022. The underlying press release was furnished as Exhibit 99.1, but its financial details are not included in the provided filing text.
Financial Metrics
The provided text does not provide clear values for revenue, net loss or profit, operating expenses, cash flow, margins, debt, cash and investments, liquidity, or other financial metrics. Investors should refer to Exhibit 99.1 or the company’s related periodic filing for those amounts.
Material Changes Versus Prior Comparable Period
The filing text does not provide financial comparisons or quantitative changes versus the fourth quarter or full year ended December 31, 2021.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are described in the provided Form 8-K text. The filing is limited to announcing the financial-results press release and furnishing that release as an exhibit.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for fourth-quarter and full-year 2022 financial results.
- Verify cash, cash equivalents, investments, operating cash burn, and expected liquidity runway.
- Review reported research and development and general and administrative expenses and year-over-year changes.
- Check for management’s clinical-development updates, guidance, financing plans, and risk disclosures in the press release and related annual report.
- Note that the information in Items 2.02 and 9.01, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.